Advanced searches left 3/3

Double Vision - Europe PMC

Summarized by Plex Scholar
Last Updated: 24 October 2022

* If you want to update the article please login/register

Quality of Vision After LASIK, PRK and FemtoLASIK: An Analysis Using the Double Pass Imaging System HD AnalyzerTM ® .

The objective quality of vision assessment, the modular transfer function cutoff frequency, and the estimated visual acuity within the 90 percent, 20%, and 9% comparison results that were assessed at baseline, 1st week, 1 and 6 months after surgery were all included. Higher MTF values [F=6. 635, p=0. 003], higher PVA 20. 73 vs. 32. 41 and 30. 28 ], and PVA 9% [F=6. 07, p=0. 001] and PVA 19. 33 [F=6. 636, p=0. 003], higher MTF values [F=6. 641], higher PVA 0. 83, p=0. 001], higher PVA 0. 83 (b01. 41, p=0. 001, u00b111. 4] and PVA [M1] and P=0. 63] and P=0. 001]. Conclusion In our study, FS-LASIK's latest optical results were found by the HD AnalyzerTM system, with marginally lower OSI and higher MTF, PVA20, and PVA9 values.

Source link: https://europepmc.org/article/MED/36237491


Comparing the vision quality using double-pass technique in eyes with corrected refractive errors and emmetropic eyes.

In patients with emmetropia and ametropia, the vision quality can be determined by measuring objective light scatter index and objective optical quality parameters. Patients underwent slit lamp examination, optical acuity, refraction, and vision quality using the HD Analyzer, with eyewitness greater than 0. 0 logMAR or better. The ametropic group, comprised of eyes with best-corrected visual acuity of 0. 0 logMAR or better, and displayed at least a refractive error of u22650. 25 D. Patients underwent slit lamp examination, visual acuity, refraction, Conclusion In spectacle-corrected conditions, emmetropic and simple myopic eyes had significantly enhanced vision quality compared to hyperopic and astigmatic eyes.

Source link: https://europepmc.org/article/MED/34852046


Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial.

Following the administration of two 1. 0-mg intravitreal doses of risuteganib, a motivation and goal were used to investigate the correlation between best-corrected visual acuity enhancement and changes in microperimetry and color vision in patients with nonexudative age-related macular degeneration. At week 16, the risuteganib group received its second 1. 0-mg dose, while patients in the sham group received 1. 0 mg of risuteganib. The risuteganib response indicator and the nonresponder showed a trend toward increase in response times and no change in the nonresponders, with significant differences between the risuteganib and control group and the response and nonresponders demonstrating significant differences. Conclusions All color vision and MP parameters tested tended to improve in risuteganib-treated patients and risuteganib responders, according to the results. In risuteganib patients, there is a strong correlation between BCVA and both TES Lanthony and Hue Style, which gives consistent evidence of objective and subjective improvement in retinal function.

Source link: https://europepmc.org/article/MED/35951718

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions